Cognition Therapeutics announces results from the SEQUEL study of CT1812
PremiumThe FlyCognition Therapeutics announces results from the SEQUEL study of CT1812
3M ago
Cognition Therapeutics price target lowered to $5 from $7 at H.C. Wainwright
Premium
The Fly
Cognition Therapeutics price target lowered to $5 from $7 at H.C. Wainwright
3M ago
Cognition Therapeutics reports Q2 EPS (18c), consensus (24c)
Premium
The Fly
Cognition Therapeutics reports Q2 EPS (18c), consensus (24c)
3M ago
Cognition downgraded to Neutral from Overweight at Cantor Fitzgerald
PremiumThe FlyCognition downgraded to Neutral from Overweight at Cantor Fitzgerald
4M ago
Cognition Therapeutics reports proof-of-concept Phase 2 trial outcome
Premium
The Fly
Cognition Therapeutics reports proof-of-concept Phase 2 trial outcome
4M ago
Cognition Therapeutics’ Phase 2 study of CT1812 in Alzheimer’s accepted at AAIC
Premium
The Fly
Cognition Therapeutics’ Phase 2 study of CT1812 in Alzheimer’s accepted at AAIC
4M ago
Cognition Therapeutics management to meet with Oppenheimer
PremiumThe FlyCognition Therapeutics management to meet with Oppenheimer
6M ago
Cognition Therapeutics management to meet with Oppenheimer
Premium
The Fly
Cognition Therapeutics management to meet with Oppenheimer
6M ago
Cognition Therapeutics management to meet with Oppenheimer
Premium
The Fly
Cognition Therapeutics management to meet with Oppenheimer
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100